Eterna Therapeutics Inc. Quarterly Cost of Revenue in USD from Q3 2022 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate cost of goods produced and sold and services rendered during the reporting period.
Summary
Eterna Therapeutics Inc. quarterly/annual Cost of Revenue history and growth rate from Q3 2022 to Q3 2024.
  • Eterna Therapeutics Inc. Cost of Revenue for the quarter ending September 30, 2024 was -$60K, a 150% decline year-over-year.
  • Eterna Therapeutics Inc. annual Cost of Revenue for 2023 was $236K.
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$60K -$180K -150% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-12
Q2 2024 $95K Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $61K +$11K +22% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q3 2023 $120K +$120K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q1 2023 $50K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q3 2022 $0 Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.